UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.